Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Urinary Complement Factor H in Renal Disease

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Complement factor H (hCFH) plays a key inhibitory role in the control of the alternative complement pathway. We examined whether urinary hCFH (U-hCFH) levels is useful as an indirect indicator of renal damage. Methods: Urine samples were obtained from 104 patients with renal disease. Urine was collected with 10 m M EDTA and U-hCFH levels were measured using the BTA TRAK Assay Kit. Results: In the 62 patients with nephritis, the levels of U-hCFH were elevated (range 15–52,198 U/ml) over the normal range (0–14 U/ml). U-hCFH levels of patients with chronic renal failure, lupus nephritis, membranoproliferative glomerulonephritis, focal glomerulosclerosis were higher than that of IgA nephropathy patients (p < 0.05). In the patients with minimal change disease, showed high levels of U-hCFH during the nephrotic syndrome. U-hCFH was correlated significantly with urinary protein and urinary N-acetyl-β- D-glucosaminidase. Conclusion: We demonstrated that U-hCFH was detected in the urine of nephritis patients.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          2002
          September 2002
          26 September 2002
          : 92
          : 3
          : 705-707
          Affiliations
          Division of Nephrology, Internal Medicine II, Nihon University School of Medicine, Tokyo, Japan
          Article
          64090 Nephron 2002;92:705–707
          10.1159/000064090
          12372960
          © 2002 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 1, References: 5, Pages: 3
          Product
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/64090
          Categories
          Short Communication

          Cardiovascular Medicine, Nephrology

          Urine, Nephritis, Complement activation, Complement factor H

          Comments

          Comment on this article